Wesana Health's Dr. ABID NAZEER – The Parallels Between Brain Injury & Addiction (WESA)
Dr. Nazeer is the Founder and President of APS Ketamine/Advanced Psychiatric Solutions, which
was recently acquired by Wesana Health (OTC: WSNAF, CSE: WESA), where he now assumes the role of Chief Medical Officer.
Dr. Nazeer is nationally known as a spokesperson in the areas of ketamine therapy, addiction medicine, pharmacogenomics, and psychiatry. Currently, he is running clinical research on the Relation of IV Ketamine to Neurocognitive Performance.
Dr. Nazeer is also providing medical oversight to the growth plan of Wesana Clinics.
Wasana is a company focused primarily on treating Traumatic Brain Injury (TBI) with Psychedelics. To start, they are testing psilocybin to treat TBI, though they have also recently partnered with MAPS to use MDMA.
Wesana is a company run by Daniel Carcillo, a Stanley Cup winning NHL player, and is partially funded by Mike Tyson.
In this preview with Psychedelic Spotlight, Dr Nazeer and Matthew of Psychedelic Spotlight discuss the shifting perception of psychedelics as medicines. Dr Nazeer actually opened the first Ketamine Clinic in Chicago 5 years ago. At the time everyone thought he was crazy. Now they recognize him as a trailblazer.
Nazeer claims that we are at “the turning point” for psychedelic medicines, and thinks we are 5 years away from these treatments becoming mainstream.
acquisition of Wesana
Can psychedelics treat mental health issues?
Can Psilocybin treat TBI?
These are the questions Dr. Nazeer and Wesana Health aim to answer.
#WesanaHealth #Psychedelics #addiction
Have you heard about our new community?
We’re excited to announce Bonfire -
a personal growth community for people who are interested in psychedelics.
Join us for our launch event on July 18th, where we’ll share about the work we’ll be doing together to actualize our personal missions, grow, and heal together.
Psychedelic Spotlight is your reliable source for the latest stories in the emerging psychedelics industry, covering breakthrough discoveries, investor news and cultural reform.